Omneity® Pellets
All-In-One Vitamin & Mineral Pellet
Topic:Growth Hormone
Growth hormone (GH) in horses is a peptide hormone produced by the pituitary gland, playing a significant role in growth, metabolism, and overall development. It influences various physiological processes, including protein synthesis, cell growth, and the regulation of bone and muscle development. In equine physiology, GH impacts energy metabolism and can affect performance and recovery. Researchers study the secretion patterns, regulatory mechanisms, and effects of GH to understand its role in equine health and performance. This page compiles peer-reviewed research studies and scholarly articles that explore the biology, regulation, and implications of growth hormone in horses, providing insights into its effects on growth, metabolism, and athletic performance.
Effects of short-term feed deprivation and melatonin implants on circadian patterns of leptin in the horse. Leptin is a protein hormone produced by adipose tissue that influences hypothalamic mechanisms regulating appetite and energy balance. In species tested thus far, including horses, concentrations of leptin increase as animal fat mass increases. The variables and mechanisms that influence the secretion of leptin are not well known, nor is it known in equine species how the secretion of leptin is influenced by acute alterations in energy balance, circadian patterns, and/or reproductive competence. Our objectives were to determine in horses: 1) whether plasma concentrations of leptin are secreted...
Age-related changes in serum insulin-like growth factor-I, insulin-like growth factor-I binding protein-3 and articular cartilage structure in Thoroughbred horses. Structural changes in articular cartilage associated with the ageing process require definition for investigators performing developmental and age-related studies, for which information is lacking. Objective: To 1) determine the onset and end of puberty as defined by serum insulin like growth factor (IGF-I) and IGF-binding protein-3 (IGFBP-3) concentrations and 2) correlate articular-epiphyseal cartilage complex structural changes with the onset and end of puberty. Methods: IGF-I and IGFBP-3 were measured in serum samples from normal female and male horses age 9-715 days to determine peak and ...
Growth rate consists of baseline and systematic deviation components in Thoroughbreds. The objective of this study was to establish a procedure for differentiating a baseline curve from a systematic deviation in weight-age data, and hence to develop a physiological growth model for the Thoroughbred. A total of 2,698 records for 175 foals was obtained during a period of 8 yr (1994 to 2001). Weight-age data were fit with a sigmoid growth equation, W = A(1 + be(-kt))M, where W is BW at age t, A is the asymptotic value of W, b is a scaling parameter that defines the degree of maturity at t = 0, k is a rate constant, and M defines the point of inflection in the sigmoid curve in relat...
Thyrotropin releasing hormone interactions with growth hormone secretion in horses. Light horse mares, stallions, and geldings were used to 1) extend our observations on the thyrotropin releasing hormone (TRH) inhibition of GH secretion in response to physiologic stimuli and 2) test the hypothesis that stimulation of endogenous TRH would decrease the normal rate of GH secretion. In Exp. 1 and 2, pretreatment of mares with TRH (10 microg/kg BW) decreased (P < 0.001) the GH response to exercise and aspartate infusion. Time analysis in Exp. 3 indicated that the TRH inhibition lasted at least 60 min but was absent by 120 min. Administration of a single injection of TRH to stal...
Models of fetal growth restriction. The growth of the fetus is determined by substrate supply mostly for mass accretion and energy gain, and by control systems. Experiments with whole animal models will face the following problems: (1) The fetus, like a three compartmental "Russian doll", is at the end of a long supply chain. There are interactions (e.g. hormones) and partitioning of substrates between the compartments. (2) The fetal organism is growing and differentiating at the same time and not in a steady-state. Experimental results thus depend on gestational age. (3) About 75% of animal experiments on fetal growth restricti...
Effects of lactation on metabolic and reproductive hormones in Lipizzaner mares. In this study, growth hormone (GH), insulin-like growth factor 1 (IGF-1), leptin, luteinising hormone (LH) and prolactin were analyzed in mares from late pregnancy throughout lactation (group 1, n=46) and in non-lactating mares (group 2, n=11). Plasma GH concentrations in group 1 mares during gestation and lactation were lower than in mares of group 2 (P<0.05). Highest IGF-1 levels were found in lactating mares in the week of foaling. IGF-1 concentrations decreased continuously thereafter. Plasma leptin concentrations decreased after foaling and, for 4 weeks, were lower in lactating than in...
The effect of dietary energy source on serum concentration of insulin-like growth factor-I growth hormone, insulin, glucose, and fat metabolites in weanling horses. Feeding diets high in soluble carbohydrates to growing horses has been implicated in the development of orthopedic diseases; as a result, substitution of dietary fat for soluble carbohydrates has received attention. Because IGF-I is integral to growth and cartilage development and because it is influenced by nutrition, we evaluated the effect of dietary fat substitution on metabolic endpoints and circulating GH and IGF-I in growing horses. Twelve Quarter Horse weanlings, four female and eight male, 151 to 226 d old, were blocked by sex and age and assigned to two treatment groups. Group one (C...
Effect of growth hormone (GH) on in vitro nuclear and cytoplasmic oocyte maturation, cumulus expansion, hyaluronan synthases, and connexins 32 and 43 expression, and GH receptor messenger RNA expression in equine and porcine species. The aim of this study was to investigate the role of growth hormone (GH) on in vitro cumulus expansion and oocyte maturation in equine and porcine cumulus-oocyte complexes (COCs), and to approach its way of action. Equine COCs were cultured in a control medium (TCM199, 5 mg/ml BSA, 1 microg/ml estradiol, and antibiotics) supplemented with either 0.5 microg/ml equine GH or 5 microg/ml equine LH. Porcine COCs were cultured in a basal medium (TCM199 with 570 microM cysteamine) supplemented with 0, 0.1, 0.5, or 1 microg/ml porcine GH or in a control medium (basal medium with 10 ng/ml epidermal gro...
Recombinant equine growth hormone administration: effects on synovial fluid biomarkers and cartilage metabolism in horses. Recombinant equine growth hormone (reGH) has recently been evaluated for effects on body condition and wound healing. It has the potential to influence articular cartilage via stimulation of IGF-1. Objective: To investigate effects of administration on synovial joint metabolism. Methods: Six mature horses were given 20 microg/kg bwt reGH daily for 8 weeks by i.m. injection. Three control horses were injected with sterile water. Serum and synovial fluid samples were collected at 6, 8, 11 and 16 weeks for GH and IGF-1 assays. Articular cartilage harvested at week 16 was evaluated by Western anal...
Somatostatin treatment affects testicular function in stallions. This study investigated the regulation of growth hormone (GH) release in stallions and tested the hypothesis that the somatotrophic axis influences testicular function. Basal plasma GH concentrations, effects of an experimental decrease of GH release on testicular function and an opioidergic regulation of GH release were investigated in Shetland stallions (n=6). No seasonal variations in plasma GH concentrations were found over a 12-month period. Treatment with the somatostatin analogue octreotid (100mg twice daily over 10 days) caused a decrease in semen motility from 38.7+/-8.4% progressivel...
High versus low body condition in mares: interactions with responses to somatotropin, GnRH analog, and dexamethasone. Mares that had previously been fed to attain body condition scores (BCS) of 7.5 to 8.5 (high) or 3.0 to 3.5 (low) were used to determine the interaction of BCS with the responses to 1) administration of equine somatotropin (eST) daily for 14 d beginning January 20 followed by administration of GnRH analog (GnRHa) daily for 21 d and 2) 4-d treatment with dexamethasone later in the spring when mares in low BCS had begun to ovulate. The majority of mares with high BCS continued to cycle throughout the winter, as evidenced by larger ovaries (P < 0.002), more corpora lutea (P < 0.05), greater proge...
The relationship between body condition, leptin, and reproductive and hormonal characteristics of mares during the seasonal anovulatory period. An experiment was conducted to determine the effects of high vs low body condition scores (BCS) produced by restricted feeding on reproductive characteristics, hormonal secretion, and leptin concentrations in mares during the autumnal transition and winter anovulatory period. Mares with BCS of 6.5 to 8.0 were maintained on pasture and/or grass hay, and starting in September, were full fed or restricted to produce BCS of 7.5 to 8.5 (high) or 3.0 to 3.5 (low) by December. All but one mare with high BCS continued to ovulate or have follicular activity during the winter, whereas mares with low BCS...
Effects of somatotropin and training on indices of exercise capacity in Standardbreds. The recent availability of recombinant equine somatotropin (eST) has led to concern about its use as an ergogenic aid in racehorses. This study was undertaken to investigate the changes in exercise capacity in maturing horses in a training programme, and to assess whether eST is an ergogenic aid to this group. We tested the hypothesis that the combination of training and eST, compared to training alone, would further improve exercise capacity in maturing Standardbreds, by virtue of ST's anabolic effects and potential to enhance cardiac function, circulating fluid volume and red cell mass. Twel...
The effect of recombinant equine growth hormone on the biomechanical properties of healing superficial digital flexor tendons in horses. To evaluate the effect of recombinant equine growth hormone (rEGH) on the in vitro biomechanical properties of healing superficial digital flexor tendon (SDFT) in horses. Methods: Completely randomized design. Methods: Twelve Standardbred horses, 3 to 7 years of age, with ultrasonographically normal forelimb SDFT. Methods: One week after induction of collagenase (2,000 U) induced superficial flexor tendonitis, horses were randomly divided into groups of 6. One group was administered intramuscular rEGH (10 microg/kg/day for 1 week, then 20 microg/kg/day for 5 weeks), whereas the other group (co...
The effect of equine recombinant growth hormone on second intention wound healing in horses. To evaluate the effect of intramuscular administration of recombinant equine growth hormone on healing of full thickness skin wounds on equine limbs. Methods: Experimental. Methods: Nine Standardbred horses. Methods: In study 1, standardized full thickness skin wounds (2.5 x 2.5 cm) were made over the dorsomedial aspect of the mid-cannon bone of 1 forelimb and 1 hindlimb in 9 horses. Wounds were bandaged without treatment (control subjects) and videorecorded twice weekly until healed. Then, in study 2, similar wounds were created on the opposite limbs; 6 horses were administered intramuscular ...
Recombinant equine growth hormone does not affect the in vitro biomechanical properties of equine superficial digital flexor tendon. To evaluate the effect of recombinant equine growth hormone (rEGH) on the in vitro biomechanical properties of normal adult equine superficial digital flexor tendon (SDFT). Methods: Completely randomized design. Methods: Nine Standardbred horses, 6 to 9 years of age with ultrasonographically normal forelimb SDFT. Methods: Six horses were administered intramuscular (IM) rEGH at 10 microg/kg/day for 1 week, and then 20 microg/kg/day for another 5 weeks; 3 horses (control subjects) were administered an equivalent daily volume of sterile water IM. Horses were killed at the end of the 6-week treatm...
Growth hormone or insulin-like growth factor-I extends longevity of equine spermatozoa in vitro. Growth hormone (GH) and insulin-like growth factor-I (IGF-I) are both present in blood plasma and IGF-I has been measured in epididymal fluid and seminal plasma. This study was designed to investigate the direct effects of GH or IGF-I on the motility of mature equine spermatozoa in vitro. We compared the effects of one concentration (100 ng/ml) of recombinant bovine GH (rbGH) and recombinant human IGF-I (rhIGF-I) on motility and motion characteristics of equine spermatozoa over a 24 h period. Motility was maintained longer in spermatozoa treated with either rbGH or rhIGF-I during a 24 h period...
Effects of frequency of treatment with recombinant equine somatotropin on selected biological responses in geldings. Two experiments compared the efficacies of different treatment frequencies for recombinant equine somatotropin (eST). In Experiment 1, five geldings received daily injections of eST at 20 microg/kg of body weight, and five received every-other-day injections at 40 microg/kg of body weight, for a total of 30 days. Plasma glucose (P=0.0001), insulin (P=0.0135), and non-esterified fatty acid (NEFA, P=0.0001) concentrations increased, and plasma urea nitrogen (PUN) concentrations decreased (P=0.0001), in both groups, and only minor differences (P<0.05) occurred between the two groups. Insulin-like...
Growth hormone response to a novel growth hormone-releasing tripeptide in horses: interaction with gonadotropin-releasing hormone, thyrotropin-releasing hormone, and sulpiride. A series of experiments was performed to determine the factor(s) responsible for an apparent inhibition of GH secretion in mares administered the GH secretagogue EP51389 in combination with GnRH, thyrotropin-releasing hormone (TRH), and sulpiride. Experiment 1 tested the repeatability of the original observation: 10 mares received EP51389 at 10 microg/kg BW; five received TRH (10 microg/kg BW), GnRH (1 microg/kg BW), and sulpiride (100 microg/kg BW) immediately before EP51389, and five received saline. The mixture of TRH, GnRH, and sulpiride reduced (P = 0.0034) the GH response to EP51389, con...
Daily treatment of growing foals with equine somatotropin: pathologic and endocrinologic assessments at necropsy and residual effects in live animals. This experiment assessed the effects of 12 mo of daily treatment of young horses with recombinant equine somatotropin (eST) on 1) carcass and internal organ traits at necropsy and 2) residual effects in live horses for 60 d after cessation of treatment. Seven horses received eST daily at 20 microg/kg BW; seven others received vehicle (controls). Four horses from each group were killed at the end of treatment. There were few effects of eST treatment on hematologic assessments or histopathologic evaluations of internal organs. Treatment with eST increased the weights of the right adrenal gland (...
Daily treatment of horses with equine somatotropin from 4 to 16 months of age. Fourteen foals between 4 and 4.5 mo of age were used to determine the effects of 12 mo of daily treatment with equine somatotropin (eST) on growth, metabolic, and hormonal characteristics. The foals were paired by sex, type, and lineage, and one of each pair was administered eST daily at 20 microg/kg of BW. Body weights, body measurements, and assessments of glucose tolerance and feedback effects on endogenous somatotropin (ST) secretion were made routinely. Treatment with eST did not alter (P > 0.10) BW, height at withers, length of body, widths of chest and rump, heart girth, length of he...
IGF -I plasma concentrations in non-treated horses and horses administered with methionyl equine somatotropin. Insulin-like growth factor-I (IGF -I) is likely to be an indicator of somatotropin (ST) administration in the horse. To investigate the different ways ST administration may be detected, the following aspects of IGF -I concentrations in plasma were studied: (i) the daily variation; (ii) variation following a treadmill test; (iii) concentrations at rest and after exercise; and (iv) concentrations in plasma from two young horses and two adults treated with methionyl equine somatotropin (e ST). In the population of horses at rest, IGF -I mean concentration (SEM) was 261 (104) ng ml(-1). In post ra...
Effects of age and recombinant equine somatotropin (eST) administration on immune function in female horses. Aging has been associated with declines in somatotropin and IGF-I levels as well as declines in immune function. To determine the effects of age and whether ST administration could reverse immunosenescence in horses, eight young and eight aged female standardbred horses were given 10 mg/d recombinant equine somatotropin (eST) or vehicle buffer for 49 d. Plasma IGF-I concentrations in both age groups were higher in eST-treated animals (P < 0.001), and higher in young eST-treated mares than in aged eST-treated mares during wk 4 to 7 (P < 0.001). There was a trend toward lower monocyte and ...
Administration of bovine, porcine and equine growth hormone to the horse: effect on insulin-like growth factor-I and selected IGF binding proteins. This study investigated the biochemical effects of administration of three types of recombinant growth hormone (GH; somatotropin) to the Thoroughbred horse. Equine or bovine or porcine GH was administered at a recommended dosage to 3-5-year old Thoroughbred geldings, for up to 21 days. It was shown that, in addition to equine GH, bovine and porcine GH were active in the horse; however, porcine GH caused injection-site reactions that were so serious that administration had to be terminated. The concentrations of a range of GH-related serum protein markers were determined before, during and afte...
Use of quantitative analysis of sonographic brightness for detection of early healing of tendon injury in horses. To determine whether quantitative analysis of sonographic brightness could be used to detect healing of an induced injury of the superficial digital flexor tendon in horses and whether rate of healing was influenced by equine recombinant growth hormone. Methods: 8 clinically normal Standardbreds. Methods: A localized injury was created in the left and right superficial digital flexor tendons of each horse by injection of 2,000 units of collagenase. After injury, 4 horses received equine recombinant growth hormone, a possible promoter of tendon healing. Sonographic images (7.5 MHz) of the flexo...
Growth hormone abuse in the horse: preliminary assessment of a mass spectrometric procedure for IGF-1 identification and quantitation. Previous studies have shown that insulin-like growth factor 1 (IGF-1) is a promising marker for the detection of growth hormone (GH) abuse in the horse. The significant increases observed with GH administration in comparison to natural levels imply the possibility of setting a threshold level for IGF-1 that would be indicative of GH abuse. Although an immunoradiometric assay (IRMA) has been identified as a reliable screening method, a more specific IGF-1 quantification method needs to be developed for the prosecution of GH abuse by horseracing authorities. This study describes such an HPLC ele...
Amino acid modifications in canine, equine and porcine pituitary growth hormones, identified by peptide-mass mapping. Modified amino acid residues in porcine, canine and equine growth hormones purified from pituitary glands were characterised by tryptic mapping and high-performance liquid chromatography with on-line coupled electrospray ionisation mass spectrometry (HPLC-ESI-MS) detection. Hormones from all three species showed the same changes. Conversion of Asp128 to iso-Asp128 was a component of native hormones, while deamidation of Asn12 and Asn98 to Asp and iso-Asp, oxidation of Met4, and cyclisation to the pyroglutamyl derivative of Gln139, probably occurred in vitro, during isolation, storage or hydrol...
Pituitary hormone and insulin responses to infusion of amino acids and N-methyl-D,L-aspartate in horses. Thirty-nine adult light horse mares, geldings, and stallions were used in two experiments to assess the pituitary hormone and insulin responses to infusions of arginine, aspartic acid, lysine, glutamic acid, and N-methyl-D,L-aspartate (NMA). In Exp. 1, 27 horses were assigned to one of three infusion treatments: 1) physiological saline (1 L); 2) 2.855 mmol of arginine/kg BW in 1 L of water; or 3) 2.855 mmol of aspartic acid/kg BW in 1 L of water. In Exp. 2, 12 horses were assigned, in a multiple-square 4 x 4 Latin square design, to one of four infusion treatments: 1) 2 mL of saline/kg BW; 2) 2...
The effects of bovine recombinant growth hormone administration on insulin-like growth factor-I and the haemopoietic system in thoroughbred geldings. The effect of intramuscularly administered recombinant bovine growth hormone (rbGH) on insulin-like growth factor-I (IGF-I) and white and red blood cell indices was studied in Thoroughbred geldings. An insulin-like growth factor binding protein (IGFBP)-blocked radioimmunoassay was modified and validated for the measurement of IGF-I in equine blood plasma. Baseline values of IGF-I and blood indices were determined over a 48 h period and then a single dose of 5 microg/kg, 10 microg/kg or 50 microg/kg of rbGH was administered. Insulin-like growth factor-I levels increased in a dose-dependent mann...
Maximal exercise transiently disrupts hormonal secretory patterns in standardbred geldings. Basal concentrations of cortisol (CORT), beta-endorphin (beta EP), growth hormone (GH) and testosterone (T) and their disruption during 32 h of recovery after treadmill exercise were investigated in 4 geldings. Blood samples were collected from resting horses every 20 min between 0600-1000 and 1500-1900 h, and hourly between 1000-1500 h on 3 consecutive days. Treadmill exercise tests comprising 2 min intervals at 30, 50, and 70% VO2max then to fatigue at 100% VO2max were conducted between 1020-1130 h on Day 2. Blood was collected before, during and 15, 30, 60 and 90 min after exercise. Mean (C...
